Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to characterize the safety, efficacy and pharmacokinetic
profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
population.